The Biotech M&A Wave: Who Is Buying Whom
Big pharma is buying aggressively to fill the patent cliff. Here is what is driving the biotech M&A wave, what acquirers actually want, and what it means for biotechs.
Big pharma is buying aggressively to fill the patent cliff. Here is what is driving the biotech M&A wave, what acquirers actually want, and what it means for biotechs.
The trends, modalities, and forces most likely to shape biotech in 2027, from obesity and protein degradation to the patent cliff, AI, and the financing cycle.
A clear-eyed look at what AI has and hasn’t delivered in drug discovery by 2026, separating genuine progress from marketing, and where it actually helps.
With the first-ever PROTAC now approved, targeted protein degradation has crossed a milestone. Here is what the modality is, who leads it, and whether it lives up to the hype.
Big pharma has spent billions acquiring radiopharmaceutical companies. Here is what these radioactive cancer drugs are, why the field exploded, and the isotope bottleneck holding it back.
The first Medicare negotiated drug prices took effect in 2026. Here is how the Inflation Reduction Act works, the pill penalty debate, and what it means for biotech strategy.
Antibody-drug conjugates are the hottest category in oncology. Here is the state of ADCs in 2026: the mega-deals, the flagship drugs, the players, and the challenges ahead.
Chinese biotech out-licensing hit a record in 2025 as Western pharma raced to license drugs from China. Here is what is driving the wave, and the tensions around it.
The GLP-1 obesity drug market is heading toward $100 billion. Here is who is actually winning in 2026 as the pill era begins, and who is fighting to catch up.